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STUDY PROTOCOL
The reconsolidation using rewind study (RETURN): trial protocol
Laurence Astill Wright a, Kali Barawi a, Natalie Simon a, Catrin Lewis a, David Mussb, Neil P. Roberts a,c, 
Neil J Kitchiner a,c and Jonathan I Bisson a
aDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK; bInternational 
Association for Rewind Trauma Therapy, UK; cDirectorate of Psychology and Psychological Therapies, Cardiff & Vale University Health 
Board, Cardiff, UK
ABSTRACT
Background: An increasing body of research highlights reconsolidation-based therapies as 
emerging treatments for post-traumatic stress disorder (PTSD). The Rewind Technique is 
a non-pharmacological reconsolidation-based therapy with promising early results, which 
now requires evaluation through an RCT.
Objectives: This is a preliminary efficacy RCT to determine if the Rewind Technique is likely 
to be a good candidate to test against usual care in a future pragmatic efficacy RCT.
Methods: 40 participants will be randomised to receive either the Rewind Technique 
immediately, or after an 8 week wait. The primary outcome will be PTSD symptom severity 
as measured by the Clinician-Administered PTSD Scale for DSM5 (CAPS-5) at 8 and 16 weeks 
post-randomisation. Secondary outcome measures include the PTSD Checklist (PCL-5), 
International Trauma Questionnaire (ITQ), Patient Health Questionnaire (PHQ-9), the 
General Anxiety Disorder-7 (GAD-7), Insomnia Severity Index, the Euro-Qol-5D (EQ5D-5 L), 
the prominence of re-experiencing specific symptoms (CAPS-5) and an intervention accept-
ability questionnaire to measure tolerability of the intervention.
Conclusions: This study will be the first RCT to assess the Rewind Technique. Using a cross- 
over methodology we hope to rigorously assess the efficacy and tolerability of Rewind using 
pragmatic inclusion criteria. Potential challenges include participant recruitment and 
retention.
Trial registration: ISRCTN91345822
El estudio Reconsolidación Usando Rebobinado (RETURN): protocolo 
de prueba
Antecedentes: Un creciente cuerpo de investigación destaca las terapias basadas en la 
reconsolidación como tratamientos emergentes para el trastorno de estrés postraumático 
(TEPT). La Técnica de Rebobinado es una terapia no farmacológica basada en la 
reconsolidación con resultados tempranos prometedores, que ahora requiere evaluación 
a través de un ECA.
Objetivos: Este es un ECA preliminar de eficacia para determinar si es probable que la 
técnica de rebobinado sea una candidata adecuada para probar en comparación con el 
cuidado habitual en un futuro ECA de eficacia pragmática.
Método: 40 participantes serán asignados al azar para recibir la técnica de rebobinado 
inmediatamente o después de una espera de 8 semanas. El resultado primario será la 
gravedad de los síntomas del TEPT según lo medido por la Escala de TEPT administrada 
por el médico para DSM5 (CAPS-5 en su sigla en inglés) a las 8 y 16 semanas posteriores a la 
aleatorización. Las medidas de resultados secundarios incluyen la Lista de Verificación de 
TEPT (PCL-5 en su sigla en inglés), el Cuestionario Internacional de Trauma (ITQ en su sigla 
en inglés), el Cuestionario de Salud del Paciente (PHQ-9 en su sigla en inglés), el Trastorno 
de Ansiedad General-7 (GAD-7 en su sigla en inglés), el Índice de Gravedad del Insomnio, el 
Euro-Qol- 5D (EQ5D-5L en su sigla en inglés), la prominencia de re-experimentar los 
síntomas específicos (CAPS-5) y un cuestionario de aceptabilidad de la intervención para 
medir la tolerabilidad de la intervención.
Conclusiones: Este estudio será el primer ECA para evaluar la Técnica de Rebobinado. 
Utilizando una metodología cruzada, esperamos evaluar rigurosamente la eficacia 
y tolerabilidad del Rebobinado utilizando criterios de inclusión pragmáticos. Los desafíos 
potenciales incluyen el reclutamiento y la retención de los participantes.
Registro de prueba: ISRCTN91345822
使用Rewind进行 (记忆) 再固化的研究 (RETURN) ：试验方案 
背景: 越来越多的研究强调, 基于 (记忆) 再固化是创伤后应激障碍 (PTSD) 的新兴疗法。 
Rewind 技术 (Rewind Technique) 是一种非药物的基于再固化的疗法, 具有可喜的早期结 
果, 现在需要通过RCT进行评估。
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目的: 本初步效能RCT的结果用于确定Rewind技术是否可能在将来的实用效能RCT中作为潜 
在选择方案针对常规护理进行对比评估。
方法: 40名参与者将被随机分配为立即接受Rewind 技术或等待8周。主要结果将是PTSD症 
状严重程度, 在随机分配后8周和16周由DSM-5的临床PTSD量表 (CAPS-5) 测得。次要结果 
指标包括PTSD检查表 (PCL-5), 国际创伤问卷 (ITQ), 患者健康问卷 (PHQ-9), 广泛性焦虑障 
碍量表7 (GAD-7), 失眠严重度指数, Euro-Qol- 5D (EQ5D-5L), 出现特定再体验症状的显著性 
(CAPS-5) 和测量干预耐受度的干预接受度问卷。




1. Background and rationale
Post-traumatic stress disorder (PTSD) is a common 
mental illness occurring after a traumatic event, with 
symptoms of re-experiencing, hyper-arousal, negative 
alterations in cognition and mood, and avoidance. It 
has been estimated that between 1.1% and 2.9% of EU 
adults suffer from PTSD (Wittchen et al., 2011) and the 
prevalence of PTSD in high-risk populations such as 
those exposed to certain types of interpersonal trauma, 
mass conflict and displacement are estimated to be much 
higher (Kessler et al., 2017; Steel et al., 2009). PTSD is 
associated with substantial physical and psychiatric co- 
morbidity, for example type 2 diabetes, ischaemic heart 
disease, somatic symptom disorder, substance abuse and 
suicide (Roberts et al., 2015) and research suggests that 
current psychological and pharmacological treatments 
remain ineffective in a substantial proportion of those 
with PTSD (Olff et al., 2019, Lewis et al. 2020). Trauma- 
focused psychological therapies in the form of individual 
trauma-focused cognitive behavioural therapy (TFCBT) 
and eye movement desensitisation and reprocessing 
(EMDR) are currently the most effective treatments for 
PTSD symptoms with pharmacological approaches 
effective but to a lesser degree (National Institute for 
Health and Care Excellence (NICE), 2018, Bisson et al. 
2019). Sadly, many people with PTSD remain sympto-
matic, despite evidence-based treatment, partially due to 
high drop out rates in trauma-focused therapies, which 
appear particularly difficult to tolerate (Lewis et al. 2020). 
There is an urgent need to develop more effective treat-
ments (Olff et al., 2019), which are shorter in duration 
and less emotionally distressing (Lewis et al. 2020).
The positive outcomes of recent studies of novel treat-
ments have raised interest in the mechanism and study of 
memory reconsolidation and further work in this area is 
merited to establish the exact mechanism of action 
(Brunet et al., 2018; Gray, Budden-Potts, & Bourke, 
2017). As memory reconsolidation has been specifically 
targeted by some novel treatments (Gray et al., 2017) 
which have many similarities to the Rewind technique 
(the psychological intervention assessed here) we will 
consider reconsolidation theory in detail below.
Memory consolidation is the process where short- 
term memories are converted into long-term ones, 
while in memory reconsolidation long-term memories 
are reactivated, changed and then updated. Memories of 
stressful and fearful events have a large degree of salience 
and so are laid down particularly concretely within the 
biology of the brain, giving rise to PTSD symptoms. 
Fearful memories are made in periods of high emotional 
arousal and the formation of these is strengthened by the 
stress hormones that contribute to initial memory con-
solidation. Cortisol (De Quervain et al., 2003) and adre-
naline are released during periods of significant stress, 
and these regulate memory consolidation by causing 
noradrenergic excitement of the basolateral amygdala 
(McGaugh, 2015; Roozendaal & Hermans, 2017; 
Schwabe & Bolam, 2017). While this is not exclusive to 
fearful memories, and heightened memory consolidation 
occurs in a variety of emotional experiences, it is argued 
that disrupted memory consolidation plays a key role in 
the development and maintenance of the characteristic 
symptoms of PTSD, such as hyperarousal and re- 
experiencing (Pitman, 2019).
Despite this, emotional memory is highly malleable 
(Pitman, 2019) and a number of medications are 
believed to be able to interrupt reconsolidation, with 
the potential therapeutic effect of decreasing PTSD 
symptoms. Animal research has shown that neuroplas-
ticity is not only required for the creation of new emo-
tional memories but also for the removal of fear 
memories (Nader, Schafe, & Le Doux, 2000). The neu-
roplasticity of memory consolidation requires protein 
synthesis, a process which can be interrupted to prevent 
learning consolidation and create amnesia of a fearful 
event (Nader et al., 2000). Furthermore, when already 
consolidated fear memories are remobilised, new pro-
tein synthesis can facilitate reconsolidation, providing 
an opportunity to reconsolidate memories and decrease 
their emotional salience (Nader et al., 2000). Once 
a memory becomes reactivated and the memory is 
returned to a mobilised state similar to pre- 
consolidation, the protein synthesis antagonist aniso-
mycin can be given to block this reconsolidation 
(Pitman, 2019). While anisomycin’s toxicity prohibits 
its use as a therapy in humans, its action provides 
understanding of how the mobilisation of fear mem-
ories may ameliorate PTSD symptoms (Suris, Smith, 
Powell, & North, 2014). While exposure-based 
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therapies may inhibit the body’s reaction to the trau-
matic memory, or impair its retrieval (de Quervain, 
Schwabe, & Roozendaal, 2017), memory reconsolida-
tion treatments aim to mobilise traumatic memories to 
remove these pathognomonic symptoms entirely (de 
Quervain et al., 2017; Pitman, 2019).
It may, however, not be necessary to use pharmacolo-
gical approaches to augment/facilitate reconsolidation. 
Non-pharmacological approaches may also be effective 
and would likely be preferred and better tolerated by 
many people with PTSD (Feeny, Zoellner, & Shoshana, 
2009), and avoid the contraindications for some 
pharmacotherapies (e.g. asthma with propranolol). 
Reconsolidation of Traumatic Memories (RTM) is a non- 
pharmacological approach that aims to treat PTSD 
through memory reconsolidation over three sessions 
(Gray, 2011). The proven mechanism of RTM remains 
unclear, however, and additional factors, such as the reac-
tivation and redistribution of emotional memories in the 
neocortex during sleep, may also play a role (Schafer et al., 
2020). RTM (Gray, 2011) has RCT evidence of effect 
leading to it being recommended as a treatment with 
emerging evidence by the ISTSS Treatment Guidelines 
for PTSD and for military populations (Bisson et al, 
2019; Kitchiner, Lewis, Roberts, & Bisson, 2019). RTM is 
a development of the Rewind Technique, another non- 
pharmacological approach, with many similarities in its 
delivery to RTM, but with an evidence base that is cur-
rently reliant on non-randomised trials (Adams & Allan, 
2018; Utuza,, Joseph, & Muss, 2012). RTM and Rewind 
both employ ‘rewinding’ techniques (where the participant 
plays their trauma memory in reverse) using different 
intervention protocols.
The Rewind Technique and RTM seek to briefly mobi-
lise traumatic memories, before exploring dissociative 
experiences surrounding the trauma which are proposed 
to modify the memory, reconsolidating it so that it can be 
remembered without evoking PTSD symptomatology 
(Tylee, Gray, Glatt, & Bourke, 2017). The brief memory 
mobilisation stimulus is thought to be too brief to produce 
effects via improving the extinction of the traumatic mem-
ory (Merlo, Milton, Goozée, Theobald, & Everitt, 2014), 
and follow up suggests that the rapid reacquisition or 
reinstatement of traumatic memories, that might be 
expected if the underlying mechanism was one of memory 
extinction, does not occur (Gray et al., 2017).
Some reconsolidation approaches have yielded 
negative results (Bos, Beckers, & Kindt, 2014; Wood 
et al., 2015) highlighting the specific limitations 
which exist around the ability of a therapy to desta-
bilise and modify a traumatic memory. These factors, 
such as the length of the memory reactivation proce-
dure and the age and context of the traumatic mem-
ory, are known as boundary conditions (Treanor, 
Brown, Rissman, & Craske, 2017) and have compli-
cated the process of translation from experimental 
into clinical settings. Promising preliminary evidence, 
however (Adams & Allan, 2018; Utuza, et al., 2012), 
suggests that if reconsolidation is the mechanism of 
action for the Rewind technique, that these condi-
tions may have been met.
While trauma-focused psychotherapies (TFCBT, 
EMDR) have medium to large effect sizes, the therapy 
requires large amounts of therapist time (Lewis et al. 
2020). We expect that Rewind will have a similar effect 
size, but be more time and cost efficient, delivering 
a trauma-focused intervention in just a few sessions. 
Furthermore, as Rewind is relatively simple to deliver it 
has potential to be delivered by lower intensity therapists 
and therefore is more easily scalable. Furthermore, evi-
dence of multiple effective therapies also provides treat-
ment choice for people with PTSD, e.g. some individuals 
may prefer Rewind as it does not require trauma disclo-
sure. Considering this, Rewind may be most suitable as 
a first-line intervention as part of a stepped care approach.
Given the promise of non-pharmacological 
approaches to the treatment of PTSD through the 
mechanism of memory reconsolidation, we aim to 
undertake a preliminary efficacy RCT to determine 
if the Rewind Technique is likely to be a good candi-
date to test against usual care in a future pragmatic 
efficacy RCT. Our objectives are: 
1. To investigate the effect sizes of the Rewind 
Technique at reducing PTSD symptoms in people with 
PTSD.
2. To establish whether any symptom improve-
ment is maintained over 16 week follow up.
3. To investigate the impact of the Rewind Technique 
on symptoms of depression, anxiety and insomnia.
4. To investigate if an efficacy RCT is feasible and 
indicated.
5. To assess if the Rewind Technique is acceptable 




The study will be a two-armed, phase 2 exploratory RCT to 
assess the preliminary efficacy, adherence, feasibility and 
factors affecting outcome of the Rewind Technique versus 
a waitlist control group (Table 1).
2.2. Setting
Participants will be people with PTSD living in South 
Wales. Recruitment will primarily occur through 
University Health Boards in South Wales using 
approaches that have proved successful in other RCTs 
run by Cardiff University’s Traumatic Stress Research 
Group (Lewis et al., 2017; Nollett et al., 2018).
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2.3. Sample size
While a definitive power calculation is not necessary for 
a phase 2 exploratory trial, it is nonetheless important to 
ensure our sample size is appropriate and adequate. We 
conservatively based this power calculation on the broad 
range of effect sizes reported for trauma-focused psycho-
logical therapies for PTSD. While it is difficult to compare 
the wide range of effect sizes reported in heterogeneous 
trials, as meta-analyses demonstrate (Lewis et al. 2020, 
Mavranezouli et al., 2020), we considered an effect size of 
1.45 highly clinically relevant.
Using the Lehr method to give a sample size with 
80% power, a 5% significance level and an effect size of 
1.5, 15 participants are required in each arm of the trial, 
with a total number of 30. Estimating a conservative 
25% attrition rate, informed by recent similar research 
(Lewis et al. 2020), we will include 20 participants in 
each arm of the trial, giving 40 participants in total.
2.4. Inclusion/exclusion criteria
In order to determine the likely efficacy of the Rewind 
Technique for people with PTSD presenting to the UK’s 
National Health Service (NHS) we will adopt a pragmatic 
approach and employ broad eligibility criteria.
Inclusion criteria will be: adults aged 18 or over 
who are fluent in English, able to provide informed 
consent, and who meet DSM-5 criteria for PTSD 
secondary to a single traumatic event.
Exclusion criteria will be: current psychotic or 
bipolar disorder, traumatic brain injury, substance 
dependence, acute suicidal ideation, learning dis-
ability, previous or current receipt of an adequate 
trial of trauma-focused psychological treatment for 
PTSD, change to the type or dosage of psychotro-
pic medication within one month of baseline 
assessment. The presence of other mental disor-
ders will be allowed as long as PTSD is the pri-
mary condition, and pretreatment comorbidity 
will be assessed using clinical presentation and 
self-report.
2.5. Recruitment and consent
Potential study participants who are thought likely to fulfil 
the inclusion criteria for the trial will be asked by a clinician 
involved in their care if they are willing for their details to 
be passed on to the research team. Participants will also be 
recruited via the National Centre for Mental Health 
(NCMH), a Welsh government-funded research centre 
(NHS Health Research Authority, 2016), which recruits 
through primary and secondary mental health services as 
well as through a variety of media outlets and online 
advertising strategies. The research team will contact 
potential study participants and provide them with an 
information leaflet about the research. After 24 hours 
they will be asked if they would like any further informa-
tion or have any queries they would like answered. If 
potential participants wish to proceed, arrangements will 
be made to enter them into the study through recruitment 
screening.
Participants will provide fully informed consent to 
take part in the study before their initial assessment. 
The individual taking consent will check that the parti-
cipant has read and understood the information sheet 
provided and answer any participant questions that 
arise. They will check the participant’s understanding 
that their participation is voluntary and that they are 
free to withdraw (on a variety of levels) at any time 
without giving any reason (without their medical care 
or legal rights being affected), and ask if the participant 
agrees to their GP being informed of their participation 
in the study. Data will be handled with full compliance 
to the General Data Protection Regulations 2016.
2.6. Outcome measures
A trained member of the research team, blind to rando-
mization, will conduct all clinical assessments. It is not 
possible for therapists or participants to be blind to 
treatment allocation, but participants will be asked not 
to discuss their allocation with their assessor. An initial 
telephone screen will confirm that the participant meets 
the inclusion criteria. To ensure they consistently meet 
Table 1. Gantt chart illustrating study timeline.




and training a 
research team.
Recruitment, treatment and assessment of participants 
(follow up at 8 and 16 weeks)
Quantitative and 
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the inclusion criteria, participants will be asked to moni-
tor their symptoms for two weeks, at which point we will 
take informed consent, collect baseline demographic 
data, outcome measurements, reassess eligibility, and 
then randomise eligible individuals to one of two groups 
using a computer programme: the Rewind Technique 
immediately or a waitlist for eight weeks followed by the 
Rewind Technique. We will monitor change in PTSD, 
depressive and anxiety symptoms using the PTSD 
Checklist (PCL-5), Patient Health Questionnaire (PHQ- 
9), and General Anxiety Disorder-7 (GAD-7) at the start 
of each treatment session. Follow-up and repeated col-
lection of outcome data will occur 8 and 16 weeks post- 
randomisation.
The primary outcome of PTSD symptom severity, and 
PTSD diagnosis will be measured by trained assessors 
using the Clinician Administered PTSD Scale for DSM-5 
(CAPS-5) (Weathers et al., 2018). The CAPS-5 is widely 
referred to as the gold standard in PTSD assessment, 
demonstrating high internal consistency (α =.88) and 
strong test-retest reliability (к = .83) (Weathers et al., 
2018). Measuring DSM-5 PTSD allows comparability 
with previous psychological therapy RCTs.
Secondary outcomes, collected at 8 and 16 weeks will 
include:
The PTSD Checklist (PCL-5), a validated and widely 
used self-report measure for DSM-5 PTSD symptoms 
(Ruggiero, Del Ben, Scotti, & Rabalais, 2003).
The International Trauma Questionnaire (ITQ), 
a validated self-report measure for ICD-11 PTSD 
and complex PTSD (Cloitre et al., 2018).
The Patient Health Questionnaire-9 (PHQ-9), 
a validated and widely used self-report measure for 
assessing DSM-5 depressive symptoms (Kroenke, 
Spitzer, & Williams, 2001).
The Generalised Anxiety Disorder Assessment-7 
(GAD-7), a validated and widely used self-report mea-
sure for assessing symptoms of generalised anxiety 
disorder (Spitzer, Kroenke, Williams, & Lowe, 2006).
The Insomnia Severity Index (ISI), a validated and 
widely used self-report measure for symptoms of insom-
nia, such as prolonged sleep latency and effects on func-
tioning, over the past month, using a five-point Likert scale 
(Morin, Belleville, Bélanger, & Ivers, 2011).
The five-level EQ-5D (EQ5D-5 L), a validated and 
widely used self-report measure for health-related quality 
of life. It is recognised by NICE as such and is frequently 
used in health economic analyses (EQ-5D, 2017).
An intervention acceptability questionnaire to 
gauge acceptability and feasibility of the intervention, 
as perceived by the participant, will be completed at 
the end of the final session and returned to a member 
of the research team in a sealed envelope. Feasibility 
will be partly assessed through dropout numbers.
The prominence of re-experiencing symptoms will 
be assessed through a score of ≥3 on CAPS-5 items 
B1, B2 or B3).
2.7. Intervention
The Rewind Technique – This will comprise up to 
three 60-minute sessions following a protocol devel-
oped by David Muss (Muss, 1991) which has been 
modified by David Muss and the research team fol-
lowing feedback from therapists. The intervention 
will be administered by experienced and trained 
psychological therapists under the supervision of 
David Muss and the Cardiff and Vale University 
Health Board Traumatic Stress Service. The partici-
pant will be introduced to the technique and the 
theory behind it before being asked to imagine he/ 
she is in a cinema watching a film of her/his trau-
matic event as if it had been captured on CCTV. 
Rather than the film start at the trauma itself the 
person with PTSD is told the film starts just before 
the traumatic event took place and is then followed 
by the regular intrusive recall which includes all the 
images, sounds and smells plus (if this is part of the 
regular recall) what could have happened next but 
didn’t. Once the recall ends, the sufferer is (meta-
phorically) invited to enter the screen and at that 
point the film is rewound at speed back to the exact 
starting point (where all was well before the trauma). 
The forward part of the process of recalling the 
trauma should not take longer than 2 minutes, the 
rewind part about 10 seconds. This usually requires 
the person with PTSD to practise the technique a few 
times before feeling confident it is being undertaken 
as intended.
Wait list – The wait list group will receive no 
intervention for 8 weeks after randomisation, at 
which point they will then receive the Rewind 
Technique in the same manner as the immediate 
treatment group.
Participants will be randomised to receive either 
the Rewind Technique or wait list using a 1:1 ratio.
2.8. Study timeline
Once ethical approval is granted, the study is planned 
to take place over 18 months, with data collection 
completed within 12 months, and the remaining time 
being used for data analysis, report preparation and 
early dissemination as illustrated by the Gantt chart 
below.
2.9. Planned analyses
We will conduct intention-to-treat analyses on all 
randomised participants. We will compare the 
means of continuous data using ANCOVA with base-
line outcomes (such as CAPS-5 score) as co-variates. 
Risk ratios will be calculated for categorical data. The 
factors associated with reduction in symptom severity 
scores will be analysed using regression (baseline 
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CAPS-5 score, age, prominence of re-experiencing 
symptoms, depressive symptoms, educational attain-
ment and employment status), with all analyses per-
formed at the end of data collection using SPSS. The 
dataset will be cleaned and then ‘locked’ before the 
randomisation codes are revealed and the final ana-
lyses undertaken. This will ensure those conducting 
the analysis are blind to condition.
2.10. Dissemination of findings
Research findings will initially be communicated in 
lay terminology to study participants, with a research 
report and an end of study meeting. Participants and 
the public will be involved in the dissemination of the 
research findings in collaboration with the Cardiff 
University Traumatic Stress Research Group’s 
Patient and Public Involvement Group, consisting of 
five members of the public with lived experience of 
PTSD. We will present the work at academic confer-
ences and facilitating workshops to inform future 
work in this area.
We will publicise both the running of the trial and 
its results through the NCMH communications team. 
Furthermore, there will be a study-specific webpage, 
under the NCMH website, which will congregate all 
the information around the trial, including lay and 
academic summaries and press releases.
2.11. Data management
Personal data will be stored on University computers, 
with personal data kept separately to anonymised 
clinical data. Only the direct care and research team 
will have access to participants’ personal data during 
the research study.
3. Discussion
This phase 2 exploratory trial will assess the preli-
minary efficacy, acceptability and feasibility of the 
Rewind Technique to determine if an effectiveness 
RCT is indicated. If a phase 3 RCT is warranted, 
investigating possible effect sizes of the intervention 
in this trial will enable us to conduct an appropriate 
power calculation. This will be the first RCT evaluat-
ing Rewind, with previous non-randomised work 
highlighting the need for randomised trials, particu-
larly those with long term follow up (Adams & Allan, 
2018). Previous pilot work has assessed outcomes 
2 weeks post-intervention, while we will follow-up 
participants 8 and 16 weeks post-randomisation. 
While RTM has been investigated in randomised 
trials and shares many characteristics with Rewind 
(Gray, 2011), it is fundamentally a different interven-
tion and both require evaluation separately.
We will also improve on previous research by 
using the ‘gold standard’ of PTSD assessment, the 
CAPS-5, to measure our primary outcome. Previous 
pilot work shows the intervention to be well tolerated 
(Adams & Allan, 2018), and our involvement of 
patient and public representatives in the production 
of our participant information sheets, consent forms 
and trial protocol aims to improve the acceptability of 
recruitment and the intervention itself. Furthermore, 
considering the urgent need for new treatments for 
PTSD, and the current prevalence of Rewind already 
as a therapy in the UK (IARTT (International 
Association for Rewind Trauma Therapy), 2019), 
new evidence is clearly needed to assess the long- 
term effectiveness of Rewind on symptoms of 
PTSD, anxiety, depression and insomnia. While this 
trial is not powered to definitively assess effectiveness, 
it will provide the highest quality of evidence avail-
able for the Rewind technique.
This study with relatively narrow inclusion criteria 
will recruit new patients through local NHS health 
boards. Including any individual with a PTSD diagno-
sis from a singular traumatic event that does not meet 
the exclusion criteria will create a heterogeneous 
cohort, with a variety of different experiences from 
a wide possibility of traumas, representative of people 
with PTSD treated by the NHS. While this is crucial to 
create the quality of evidence required by NHS com-
missioners, there are numerous challenges associated 
with this. PTSD naturally includes those with high 
levels of avoidance and anxiety, and this may make 
recruitment and retention within the trial difficult. 
This is, however, a challenge that all trauma-focused 
psychological therapies must cope with, and the 
Rewind technique may be preferable to participants 
as it requires fewer sessions than current best evidenced 
techniques, such as trauma-focused CBT. Rewind 
potentially offers a trauma-focused intervention with-
out lengthy periods of intense imaginal exposure or 
disclosure of trauma. This may be more tolerable to 
participants, requiring less clinical contact than tradi-
tional therapies and possibly decreasing the risk of 
secondary traumatisation and compassion fatigue 
from therapists.
High levels of distress and avoidance may also 
cause some participants to struggle to appropriately 
reactivate the memory of their trauma (although 
there is clinical risk management procedure for 
adverse effects of the therapy), which we know is 
fundamental to then reconsolidate memory and thus 
reduce PTSD symptoms (Kindt & Van Emmerik, 
2016). Incorporating three Rewind sessions within 
the intervention may help to increase the likelihood 
that participants engage with this crucial memory 
reactivation. Furthermore, this trial will use therapists 
trained in the Rewind technique, with the therapy 
following a semi-structured protocol and regular 
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clinical supervision provided by the therapy’s origi-
nator. This hopes to ensure that memory reactivation 
occurs prior to reconsolidation, promote fidelity, and 
that the therapists, who will have prior training in 
other therapy modalities, avoid using these during 
sessions. The Rewind manual also attempts to 
improve tolerability and limit the distress and re- 
traumatisation that some participants experience 
with exposure work, by pausing when physiological 
arousal is reached and encouraging the participant to 
view their index trauma in the third person (Adams 
& Allan, 2018).
Other limitations of our work include those com-
mon to many empirical assessments of psychological 
therapy, such as it being almost impossible to con-
duct double-blind trials. All of the outcome assess-
ments will, however, be conducted blinded to 
intervention group and participants will be asked 
not to disclose their treatment allocation.
To conclude, this study will be the first RCT to 
assess The Rewind technique, a modality of therapy 
currently already being utilised to treat PTSD. The 
study will generate significant new knowledge, given 
its diversity of outcomes, quality of outcome mea-
surements, trial methodology and breadth of scope. 
Its challenges will include participant recruitment 
and retention, as well as ensuring strong adherence 
to the intervention protocol.
Disclosure statement
Dr David Muss founded the IARTT.
Funding
This work was supported by the UK Medical Research 
Council (MRC) Clinical Academic Mentorship Scheme.
ORCID





Neil P. Roberts http://orcid.org/0000-0002-6277-0102
Neil J Kitchiner http://orcid.org/0000-0003-0499-9520
Jonathan I Bisson http://orcid.org/0000-0001-5170-1243
Data Availability Statement
As a protocol there are no publicly available data for this 
work.
References
Adams, S., & Allan, S. (2018). Muss’ Rewind treatment for 
trauma: Description and multi-site pilot study. Journal of 
Mental Health, 27(5), 468–474. doi: 10.1080/09638237.2 
018.1487539
Bisson, J., Berliner, L., Cloitre, M., Forbes, D., Jensen, T., 
Lewis, C., . . . Shapiro, F. (2019). The International 
society for traumatic stress studies new guidelines for 
the prevention and treatment of posttraumatic stress 
disorder: Methodology and development process. 
Journal of Traumatic Stress, 32(4), 475–483. doi:10.10 
02/jts.22421
Bos, M., Beckers, T., & Kindt, M. (2014). Noradrenergic 
blockade of memory reconsolidation: A failure to reduce 
conditioned fear responding. Frontiers in Behavioural 
Neuroscience, 8, 412. doi:10.3389/fnbeh.2014.00412
Brunet, A., Saumier, D., Liu, A., Streiner, D., Tremblay, J., & 
Pitman, R. (2018). Reduction of PTSD symptoms with 
pre-reactivation propranolol therapy: A randomized con-
trolled trial. American Journal of Psychiatry, 175(5), 
427–433. doi:10.1176/appi.ajp.2017.17050481.
Cloitre, M., Shevlin, M., Brewin, C., Bisson, J., Roberts, N., 
Maercker, A., . . . Hyland, P. (2018). The International 
trauma questionnaire: Development of a self-report 
measure of ICD-11 PTSD and complex PTSD. Acta 
Psychiatrica Scandinavica, 138(6), 536–546. doi:10.11 
11/acps.12956.
De Kleine, R., Rothbaum, B., & Van Minnen, A. (2013). 
Pharmacological enhancement of exposure-based treat-
ment in PTSD: A qualitative review. European Journal of 
Psychotraumatology, 4(1), 21626. doi:10.3402/ejpt.v4i0.2 
1626
De Quervain, D., Henke, K., Aerni, A., Treyer, V., 
McGaugh, J., Berthold, T., . . . Hock, C. (2003). 
Glucocorticoid-induced impairment of declarative mem-
ory retrieval is associated with reduced blood flow in the 
medial temporal lobe. European Journal of Neuroscience., 
17(6), 1296–1302. doi:10.1046/j.1460-9568.2003.02542.x
de Quervain, D., Schwabe, L., & Roozendaal, B. (2017). 
Stress, glucocorticoids and memory: Implications for 
treating fear-related disorders. Nature Reviews. 
Neuroscience, 18(1), 7–19. doi:10.1038/nrn.2016.155
EQ-5D. 2017. EQ-5D-5L [Online]. Accessed 24/September/ 
19. Available at: https://euroqol.org/eq-5d-instruments 
/eq-5d-5l-about/.
Feeny, N., Zoellner, L., & Shoshana, K. (2009). Providing 
a treatment rationale for PTSD: Does what we say 
matter? Behaviour Research and Therapy, 47(9), 
752–760. doi:10.1016/j.brat.2009.06.007
Gray, R. (2011). NLP and PTSD: The visual-kinesthetic 
dissociation protocol. Current Research in NLP, 2, 
25–42.
Gray, R., Budden-Potts, D., & Bourke, F. (2017). 
Reconsolidation of traumatic memories for PTSD: A 
randomised controlled trial for 74 Veterans. 
Psychotherapy Research, 29(5), 621–639. doi:10.1080/ 
10503307.2017.1408973
IARTT (International Association for Rewind Trauma 
Therapy). 2019. The rewind (Closure Without 
Disclosure) for adults and children [Online]. Accessed: 
April/10/2019. Available at: http://www.iartt.com
Kessler, R., Aguilar-Gaxiola, S., Alonso, J., Benjet, C., 
Bromet, E., Cardoso, G., & Koenen, K. C. (2017). 
Trauma and PTSD in the WHO world mental health 
surveys. European Journal of Psychotraumatology, 8(5), 
1353383. doi:10.1080/20008198.2017.1353383
Kindt, M., & Van Emmerik, A. (2016). New avenues for 
treating emotional memory disorders: Towards 
a reconsolidation intervention for posttraumatic stress 
EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY 7
disorder. Therapeutic Advances in Psychopharmacology, 
6(4), 283–295. doi:10.1177/2045125316644541
Kitchiner, N., Lewis, C., Roberts, N., & Bisson, J. (2019). 
Active duty and ex-serving military personnel with 
post-traumatic stress disorder treated with psychological 
therapies: Systematic review and meta-analysis. 
European Journal of Psychotraumatology, 10(1), 
1684226. doi:10.1080/20008198.2019.1684226
Kroenke, D., Spitzer, R., & Williams, J. (2001). The PHQ-9: 
Validity of a brief depression severity measure. Journal 
of General Internal Medicine, 16(9), 606–613. 
doi:10.1046/j.1525-1497.2001.016009606.x
Lewis, C., Farewell, D., Groves, V., Kitchiner, N., 
Roberts, N., Vick, T., & Bisson, J. (2017). Internet- 
based guided self-help for posttraumatic stress disorder 
(PTSD): Randomized controlled trial. Depression and 
Anxiety, 34(6), 555–565. doi:10.1002/da.22645
Lewis, C., Roberts, N., Andrew, M., Starling, E., & Bisson, J. 
(2020). 2Psychological therapies for post-traumatic 
stress disorder in adults: Systematic review and 
meta-analysis. European Journal of Psychotraumatology, 
11, 1. doi:10.1080/20008198.2020.1729633
Lewis, C., Roberts, N., Gibson, S., & Bisson, J. (2020). 
Dropout from psychological therapies for 
post-traumatic stress disorder (PTSD) in adults: 
Systematic review and meta-analysis. European Journal 
of Psychotraumatology, 11(1), 1709709. doi:10.1080/ 
20008198.2019.1709709
Lonergan, M., Oivera-Figueroa, L., Pitman, R., & Brunet, A. 
(2012). Propranolol’s effects on the consolidation and recon-
solidation of long-term emotional memory in healthy partici-
pants: A meta-analysis. Journal of Psychiatry and 
Neuroscience, 37(6), 222–231. doi:10.1503/jpn.120111
Mavranezouli, L., Megnin-Viggars, O., Daly, C., Dias, S., 
Welton, N., Stockton, S., . . . Pilling, S. (2020). 
Psychological treatments for post-traumatic stress disorder 
in adults: A network meta-analysis. Psychological Medicine, 
50(4), 542–555. doi:10.1017/S0033291720000070
McGaugh, J. (2015). Consolidating memories. Annual Review 
Psychology, 66, 1–24. doi:10.1146/annurev-psych-010814- 
014954
Merlo, E., Milton, A., Goozée, Y., Theobald, E., & Everitt, B. 
(2014). Reconsolidation and extinction are dissociable and 
mutually exclusive processes: Behavioral and molecular 
evidence. Journal of Neuroscience, 34(7), 2422–2431. 
doi:10.1523/JNEUROSCI.4001-13.2014
Morin, C., Belleville, G., Bélanger, L., & Ivers, H. (2011). 
The insomnia severity index: Psychometric indicators 
to detect insomnia cases and evaluate treatment 
response. Sleep, 34(5), 601–608. doi:10.1093/sleep/34.5 
.601
Muss, D. (1991). A new technique for treating Post-traumatic 
Stress Disorder. British Journal of Clinical Psychology, 30, 
91–92. doi:10.1111/j.2044-8260.1991.tb00924.x
Nader, K., Schafe, G., & Le Doux, J. (2000). Fear memories 
require protein synthesis in the amygdala for reconsoli-
dation after retrieval. Nature, 406(6797), 722–726. 
doi:10.1038/35021052
National Institute for Health and Care Excellence (NICE). 
2018. Post-traumatic stress disorder (NICE Guideline. 
No. 116). Retrieved from: https://www.nice.org.uk/gui 
dance/NG116
NHS Health Research Authority. (2016). National centre 




Nollett, C., Lewis, C., Kitchiner, N., Roberts, N., Addison, K., 
Brookes-Howell, L., . . . Bisson, J. (2018). Pragmatic rando-
mised controlled trial of a trauma-focused guided self-help 
programme versus individual trauma-focused cognitive beha-
vioural therapy for post-traumatic stress disorder (RAPID): 
Trial protocol. BMC Psychiatry, 18(1), 77. doi:10.1186/s12888- 
018-1665-3
Olff, M., Amstadter, A., Armour, C., Birkeland, M., Bui, E., 
Cloitre, M., . . . Thoresen, S. (2019). A decennial review of 
psychotraumatology: What did we learn and where are we 
going? European Journal of Psychotraumatology, 10(1), 
1672948. doi:10.1080/20008198.2019.1672948
Pitman, R. (2019). Harnessing reconsolidation to treat 
mental disorders. Biological Psychiatry, 78(12), 
819–820. doi:10.1016/j.biopsych.2015.10.002.
Roberts, A., Agnew-Blais, J., Spiegelman, D., Kubzansky, L., 
Mason, S., Galea, S., . . . Koenen, K. (2015). 
Posttraumatic stress disorder and incidence of Type 2 
diabetes mellitus in a sample of women: A 22-year long-
itudinal study. JAMA Psychiatry., 72(3), 203–210. 
doi:10.1001/jamapsychiatry.2014.2632
Roozendaal, B., & Hermans, E. (2017). Norepinephrine 
effects on the encoding and consolidation of emotional 
memory: Improving synergy between animal and human 
studies. Current Opinion in Behavioral Sciences, 14, 
115–122. doi:10.1016/j.cobeha.2017.02.001
Ruggiero, K., Del Ben, K., Scotti, J., & Rabalais, A. (2003). 
Psychometric properties of the PTSD checklist-civilian 
version. Journal of Traumatic Stress, 16(5), 495–502. 
doi:10.1023/A:1025714729117
Schafer, S., Wirth, B., Staginnus, M., Becker, N., 
Michael, T., & Sopp, M. (2020). Sleep’s impact on emo-
tional recognition memory: A meta-analysis of whole- 
night, nap, and REM sleep effects. Sleep Medicine 
Reviews, 51(101280). doi:10.1016/j.smrv.2020.101280.
Schwabe, L., & Bolam, P. (2017). Memory under stress: From 
single systems to network changes. European Journal of 
Neuroscience., 45(4), 478–489. doi:10.1111/ejn.13478
Sijbrandij, M., Kleiboer, A., Bisson, J., Barbui, C., & 
Cuijpers, P. (2015). Pharmacological prevention of 
post-traumatic stress disorder and acute stress disorder: 
A systematic review and meta-analysis. Lancet 
Psychiatry, 2(5), 413–421. doi:10.1016/S2215-0366(14) 
00121-7
Spitzer, R., Kroenke, K., Williams, J., & Lowe, B. (2006). A brief 
measure for assessing generalized anxiety disorder: The 
GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. 
doi:10.1001/archinte.166.10.1092
Steel, Z., Chey, T., Silove, D., Marnane, C., Bryant, R. A., & van 
Ommeren, M. (2009). Association of torture and other poten-
tially traumatic events with mental health outcomes among 
populations exposed to mass conflict and displacement: 
A systematic review and meta-analysis. JAMA, 302(5), 
537–549. doi:10.1001/jama.2009.1132.
Suris, A., Smith, J., Powell, C., & North, C. (2014). 
Interfering with the reconsolidation of traumatic mem-
ory: Sirolimus as a novel agent for treating veterans with 
posttraumatic stress disorder. Annals of Clinical 
Psychiatry, 25(1), 33–40.PMCID: PMC3902858.
Thal, S. B., & Lommen, M. J. J. (2018). Current perspective 
on MDMA-assisted psychotherapy for posttraumatic 
stress disorder. Journal of Contemporary Psychotherapy, 
48(99), 99–108. doi:10.1007/s10879-017-9379-2
Treanor, M., Brown, L., Rissman, J., & Craske, M. (2017). Can 
memories of traumatic experiences or addiction be erased or 
modified? A critical review of research on the disruption of 
memory reconsolidation and its applications. Perspectives on 
8 L. ASTILL WRIGHT ET AL.
Psychological Science, 12(2), 290–305. doi:10.1177/1745691 
616664725.
Tylee, D., Gray, R., Glatt, S., & Bourke, F. (2017). 
Evaluation of the reconsolidation of traumatic memories 
protocol for the treatment of PTSD: A randomized, 
wait-list-controlled trial. Journal of Military, Veteran 
and Family Health., 3(1), 621–639. doi:10.1080/ 
10503307.2017.1408973
Utuza, A., Joseph, S., & Muss, D. (2012). Treating traumatic 
memories in Rwanda with the rewind technique: Two-week 
follow-up after a single group session. Traumatology, 18(1), 
75–78. doi:10.1177/1534765611412795
Weathers, F., Bovin, M., Lee, D., Sloan, D., Schnurr, P., 
Kaloupek, D., . . . Marx, B. (2018). The Clinician-adminis-
tered PTSD scale for DSM-5 (CAPS-5): Development and 
initial psychometric evaluation in military veterans. 
Psychological Assessment, 30(3), 383–395. doi:10.1037/ 
pas0000486
Wittchen, H., Jacobi, F., Rehm, J., Gustavsson, A., 
Svensson, M., Jönsson, B., . . . Fratiglioni, L. (2011). 
The size and burden of mental disorders and other 
disorders of the brain in Europe 2010. European 
Neuropsychopharmacology, 21(9), 655–679. doi:10.101 
6/j.euroneuro.2011.07.018
Wood, N., Rosasco, M., Suris, A., Spring, J., Marin, M., 
Lasko, N., . . . Pitman, R. (2015). Pharmacological 
blockade of memory reconsolidation in posttraumatic 
stress disorder: Three negative psychophysiological 
studies. Psychiatry Research, 225(1–2), 31–39. 
doi:10.1016/j.psychres.2014.09.005
EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY 9
